JP5837877B2 - 静脈内投与イブプロフェンを用いた患者の治療 - Google Patents

静脈内投与イブプロフェンを用いた患者の治療 Download PDF

Info

Publication number
JP5837877B2
JP5837877B2 JP2012520637A JP2012520637A JP5837877B2 JP 5837877 B2 JP5837877 B2 JP 5837877B2 JP 2012520637 A JP2012520637 A JP 2012520637A JP 2012520637 A JP2012520637 A JP 2012520637A JP 5837877 B2 JP5837877 B2 JP 5837877B2
Authority
JP
Japan
Prior art keywords
ibuprofen
dose
patient
pharmaceutical composition
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012520637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533542A5 (enExample
JP2012533542A (ja
Inventor
パヴリヴ，レオ
ロック，エイミー，ディクス
Original Assignee
カンバーランド ファーマシューティカルズ，インコーポレーテッド
カンバーランド ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/570,912 external-priority patent/US20110028556A1/en
Priority claimed from US12/646,499 external-priority patent/US8871810B2/en
Application filed by カンバーランド ファーマシューティカルズ，インコーポレーテッド, カンバーランド ファーマシューティカルズ，インコーポレーテッド filed Critical カンバーランド ファーマシューティカルズ，インコーポレーテッド
Publication of JP2012533542A publication Critical patent/JP2012533542A/ja
Publication of JP2012533542A5 publication Critical patent/JP2012533542A5/ja
Application granted granted Critical
Publication of JP5837877B2 publication Critical patent/JP5837877B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012520637A 2009-07-15 2010-05-25 静脈内投与イブプロフェンを用いた患者の治療 Expired - Fee Related JP5837877B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US22577809P 2009-07-15 2009-07-15
US61/225,778 2009-07-15
US23034209P 2009-07-31 2009-07-31
US23032409P 2009-07-31 2009-07-31
US61/230,324 2009-07-31
US61/230,342 2009-07-31
US12/570,912 US20110028556A1 (en) 2009-07-31 2009-09-30 Treating critically ill patients with intravenous ibuprofen
US12/570,912 2009-09-30
US12/646,499 US8871810B2 (en) 2009-07-15 2009-12-23 Treating critically ill patients with intravenous ibuprofen
US12/646,499 2009-12-23
US12/699,595 2010-02-03
US12/699,595 US8735452B2 (en) 2009-07-15 2010-02-03 Treating patients with intravenous ibuprofen
PCT/US2010/036015 WO2011008347A1 (en) 2009-07-15 2010-05-25 Treating patients with intravenous ibuprofen

Publications (3)

Publication Number Publication Date
JP2012533542A JP2012533542A (ja) 2012-12-27
JP2012533542A5 JP2012533542A5 (enExample) 2013-03-14
JP5837877B2 true JP5837877B2 (ja) 2015-12-24

Family

ID=45773652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520637A Expired - Fee Related JP5837877B2 (ja) 2009-07-15 2010-05-25 静脈内投与イブプロフェンを用いた患者の治療

Country Status (9)

Country Link
US (2) US8735452B2 (enExample)
EP (1) EP2453742A4 (enExample)
JP (1) JP5837877B2 (enExample)
KR (1) KR20120089623A (enExample)
CN (1) CN102469781A (enExample)
AU (1) AU2010274030B2 (enExample)
BR (1) BR112012000773A2 (enExample)
CA (1) CA2767971A1 (enExample)
WO (1) WO2011008347A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754922C (en) * 2009-03-12 2016-10-18 Cumberland Pharmaceuticals Inc. Administration of intravenous ibuprofen
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
US9072661B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
CN110693822A (zh) * 2019-09-29 2020-01-17 山东罗欣药业集团股份有限公司 一种布洛芬注射液及制备方法
CN111214467A (zh) * 2020-03-05 2020-06-02 南京巴傲得生物科技有限公司 吲哚布洛芬在抵抗hmgb1促炎活性中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
DE2914788A1 (de) 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
US4861797A (en) 1987-10-15 1989-08-29 Oratech Pharmaceutical Development Corporation Liquid ibuprofen compositions and methods of making them
US4859704A (en) 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
US5200558A (en) 1989-10-17 1993-04-06 Merck & Co., Inc. S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset-hastened enhanced analgesics
IT1264857B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
IT1266583B1 (it) 1993-07-30 1997-01-09 Zambon Spa Processo per la preparazione di sali dell'acido 2-(4-isobutilfenil)- propionico
US6423746B1 (en) 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US6342530B1 (en) 2000-11-14 2002-01-29 Farmacon-Il, Llc Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt
MXPA04004024A (es) * 2001-11-02 2004-10-29 Cumberland Pharmaceuticals Inc Composicion farmaceutica de acido 2-(4-isobutilfenil) propionico.
US6727286B2 (en) * 2001-11-02 2004-04-27 Cumberland Pharmaceuticals Inc. Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
US20040132823A1 (en) 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
US8229903B2 (en) * 2002-12-19 2012-07-24 International Business Machines Corporation Suggesting data interpretations and patterns for updating policy documents
EP2630955B1 (en) 2007-08-15 2021-09-22 Johnson & Johnson Consumer Inc. Immediate release and sustained release ibuprofen dosing regimen
CN101265178A (zh) * 2008-04-25 2008-09-17 北京阜康仁生物制药科技有限公司 一种右旋布洛芬的氨基酸盐及其药用组合物

Also Published As

Publication number Publication date
CA2767971A1 (en) 2011-01-20
WO2011008347A1 (en) 2011-01-20
EP2453742A4 (en) 2012-09-05
JP2012533542A (ja) 2012-12-27
US9114068B2 (en) 2015-08-25
CN102469781A (zh) 2012-05-23
AU2010274030A1 (en) 2012-01-19
KR20120089623A (ko) 2012-08-13
BR112012000773A2 (pt) 2017-08-29
EP2453742A1 (en) 2012-05-23
US20110028557A1 (en) 2011-02-03
AU2010274030B2 (en) 2015-04-23
US8735452B2 (en) 2014-05-27
US20140235720A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
US9931311B2 (en) Treating critically ill patients with intravenous ibuprofen
US12329732B2 (en) Citrulline for treatment of sickle cell crisis
JP5837877B2 (ja) 静脈内投与イブプロフェンを用いた患者の治療
CN110996910A (zh) 抑郁障碍的治疗
JP2013500964A (ja) 静脈内イブプロフェンを用いた重篤な病気の患者の治療
ES2281775T3 (es) Metodo para tratar insuficiencia renal.
AU2021252229A1 (en) Endoxifen for the treatment of bipolar I disorder
HK1168734A (en) Treating patients with intravenous ibuprofen
HK1174493A (en) Treating critically ill patients with intravenous ibuprofen
OA19297A (en) Citrulline for treatment of sickle cell crisis.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151106

R150 Certificate of patent or registration of utility model

Ref document number: 5837877

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees